argenex (NASDAQ:ARGX) Given New $944.00 Price Target at Citizens Jmp

argenex (NASDAQ:ARGX) had its target price lifted by investment analysts at Citizens Jmp from $925.00 to $944.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s target price indicates a potential upside of 22.35% from the stock’s current price.

Several other analysts have also recently issued reports on the company. Truist Financial increased their target price on argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Morgan Stanley upped their price target on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. TD Cowen boosted their target price on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Guggenheim cut their target price on shares of argenex from $1,160.00 to $1,120.00 and set a “buy” rating for the company in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,005.06.

argenex Stock Performance

ARGX opened at $771.53 on Friday. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The firm’s fifty day moving average is $828.13 and its 200 day moving average is $809.87. The stock has a market cap of $47.74 billion, a price-to-earnings ratio of 33.13, a price-to-earnings-growth ratio of 0.71 and a beta of 0.37.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. On average, equities research analysts predict that argenex will post 3.13 earnings per share for the current year.

Institutional Trading of argenex

A number of large investors have recently made changes to their positions in ARGX. Mirae Asset Global Investments Co. Ltd. raised its position in argenex by 91.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after purchasing an additional 4,217 shares during the period. Allianz Asset Management GmbH boosted its position in shares of argenex by 21.3% during the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock valued at $2,708,000 after buying an additional 645 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock valued at $162,160,000 after buying an additional 26,343 shares during the last quarter. Alta Wealth Advisors LLC purchased a new stake in shares of argenex in the third quarter worth approximately $623,000. Finally, Fiera Capital Corp raised its holdings in shares of argenex by 12.1% in the third quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock worth $131,030,000 after buying an additional 19,180 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Q4 earnings and full‑year results topped expectations — $8.02 EPS vs. $6.05 consensus and $1.32B Q4 product sales; FY2025 product net sales of $4.2B (≈90% YoY growth). This confirms strong current cashflow and execution that investors reward. Full Year Results
• Positive Sentiment: Positive topline Phase 3 ADAPT OCULUS results for VYVGART in ocular myasthenia gravis (met primary endpoint, p=0.012) — supports planned sBLA to expand the U.S. label, which can drive additional addressable market and revenue growth. ADAPT OCULUS Press Release
• Positive Sentiment: HC Wainwright raised its price target to $940 and maintained a buy rating — a bullish analyst view that reinforces upside expectations. Benzinga
• Neutral Sentiment: Robert W. Baird nudged its target up slightly to $867 but kept a neutral rating — modestly constructive but not a strong buy signal. Benzinga
• Neutral Sentiment: Coverage pieces and previews (e.g., Yahoo/MarketBeat/Benzinga earnings previews and call materials) provide detail for investors but largely reiterate the above catalysts and guidance. What To Expect (Yahoo) Earnings Transcript
• Neutral Sentiment: Reported short‑interest data appears to show 0 shares (likely a data artifact) and provides no clear signal on investor positioning. Treat this as non‑informative until clarified.
• Negative Sentiment: Guggenheim trimmed its price target from $1,160 to $1,120 (still a buy) — a cut that could temper some upside enthusiasm despite the high absolute target. Benzinga

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.